US Bancorp’s Cytosorbents Corp CTSO Stock Holding History

US Bancorp’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$11.1K	–	4000
2023 Q4	$11.1K	Hold	10,000	–	–	﹤0.01%	3294
2023 Q3	$18.8K	Buy	+10,000	New	+$28.7K	﹤0.01%	2913

Other funds holding CTSO

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

US Bancorp's CTSO Position: Q1 2024 in Review

US Bancorp sold out of Cytosorbents Corp (CTSO) in Q1 2024, closing a stake of 10,000 shares — an estimated $11.1K sold.

US Bancorp first reported a position in CTSO in Q3 2023 and held it in 2 quarters. The position peaked at $18.8K in Q3 2023. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2024.

US Bancorp reported no remaining Cytosorbents Corp position as of Q1 2024 after selling out during the quarter.
US Bancorp sold 10,000 Cytosorbents Corp shares in Q1 2024, an estimated $11.1K.
US Bancorp first reported a position in Cytosorbents Corp in Q3 2023 and held it in 2 quarters.
US Bancorp's Cytosorbents Corp position peaked at $18.8K in Q3 2023.
50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2024.

Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.